StocksMedium•11 November 2026•
1 min read
Teva Targets Up to $7 Billion in Innovative Medicine Revenue by 2030
Key Facts
1Teva set a target of $6–7 billion in innovative medicines revenue by 2030 during its R&D Day.
Teva Pharmaceutical Industries set a target to generate between $6 billion and $7 billion in revenue from innovative medicines by 2030. The company announced the goal during its first R&D Day, according to a statement on GlobeNewswire, as part of a strategic transition into a high-velocity biopharmaceutical firm focused on its drug pipeline.
The shift aims to drive future growth and diversify the company's operations beyond its traditional generics business. Shares of TEVA closed at $42.4 on November 10, 2026, as the market evaluates the company's long-term strategic clarity and its ability to meet these distant financial milestones.